Thomas Stossel
An underappreciated dimension of biochemist Akira Endo's accomplishment in working with statins, which ultimately saved millions from death and disability, is the risk of drug development undertaken in the private sector. (Full article: 724 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
